Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA

Applied Health Economics and Health Policy

Volumn 14, Issue 3, 2016, Pages 361-373

  O’Day, Ken ^a   Levy, Wayne C ^b   Johnson, Meridith ^c   Jacobson, Arnold F ^c  

^a XCENDA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GE HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CARDIAC IMAGING; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LIFE TABLE; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SUDDEN CARDIAC DEATH; SURVIVAL; SYSTEMATIC REVIEW; AGED; CAUSE OF DEATH; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DIAGNOSTIC IMAGING; ECONOMICS; EPIDEMIOLOGY; FEMALE; MALE; MIDDLE AGED; STANDARDS; UNITED STATES; VERY ELDERLY;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; UNITED STATES;

EID: 84961139581     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-016-0234-5     Document Type: Article

References (38)

1. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158–63.
2. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98:2334–51.
3. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. J Am Coll Cardiol. 2008;51:2085–105.
4. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML, Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New Engl J Med. 2002;346:877–83.
5. Bardy GH, Lee KL, Mark DB, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New Engl J Med. 2005;352:225–37.
6. Kadish A, Schaechter A, Subacius H, Thattassery E, Sanders W, Anderson KP, Dyer A, Goldberger J, Levine J. Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47:2477–82.
7. Gialama F, Prezerakos P, Maniadakis N. The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2014;12:41–9.
8. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt S, Andrews ML, MADIT II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288–96.
9. Lorvidhaya P, Addo K, Chodosh A, Iyer V, Lum J, Buxton AE. Sudden cardiac death risk stratification in patients with heart failure. Heart Fail Clin. 2011;7(2):157–74, vii.
10. van Rees JB, Borleffs CJ, van Welsenes GH, et al. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES Risk Score. Heart. 2012;98:872–7.
11. Jacobson AF, Senior R, Cerqueira MD, ADMIRE-HF Investigators, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study. J Am Coll Cardiol. 2010;55:2212–21.
12. Ketchum ES, Jacobson AF, Caldwell JH, et al. Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol. 2012;19:1007–16.
13. Jain JK, Hauptman PJ, Spertus JA, et al. Incremental utility of iodine-123 meta-iodobenzylguanidine imaging beyond established heart failure risk models. J Cardiac Fail. 2014;20:577–83.
14. GE Healthcare US. Data on file.
15. Narula J, Gerson M, Thomas GS, Cerqueira MD, Jacobson AF. I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: the ADMIRE-HFX study. J Nucl Med. 2015;56:1011–8.
16. Gasparini M, Menozzi C, Proclemer A, et al. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT study. Eur Heart J. 2009;30:2758–67.
17. Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12:1564–70.
18. Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J Am Coll Cardiol. 2011;58:1007–13.
19. Arias E. United States life tables, 2008. National vital statistics reports, vol. 61(3). Hyattsville: National Center for Health Statistics; 2012.
20. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2009. National vital statistics reports. Vol 60(4). Hyattsville: National Center for Health Statistics; 2012.
21. Epstein AE, Kay GN, Plumb VJ, ACT Investigators, et al. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm. 2009;6:1136–43.
22. Agency for Healthcare Research and Quality. Healthcare Utilization Project. National inpatient sample. 2010. http://hcupnet.ahrq.gov/HCUPnet.jsp. Accessed 23 May 2013.
23. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. New Engl J Med. 2005;353:1471–80.
24. Rordorf R, Poggio L, Savastano S, et al. Failure of implantable cardioverter-defibrillator leads: a matter of lead size? Heart Rhythm. 2013;10:184–90.
25. Wilkoff BL, Auricchio A, Brugada J, Heart Rhythm Society (HRS), European Heart Rhythm Association (EHRA), American College of Cardiology (ACC), American Heart Association (AHA), European Society of Cardiology (ESC), Heart Failure Association of ESC (HFA), Heart Failure Society of America (HFSA), et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Europace. 2008;10:707–25.
26. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. New Engl J Med. 2008;359:1009–17.
27. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. Table 3a: mean expenses per person with care for selected conditions by type of service: United States, 2010. http://meps.ahrq.gov/mepsweb/data_stats/quick_tables_results.jsp. Accessed 31 May 2013.
28. Li Y, Levy WC, Neilson MP, et al. Associations between Seattle Heart Failure Model scores and medical resource use and costs: findings from HF-ACTION. J Cardiac Fail. 2014;20:541–7.
29. Unroe KT, Greiner MA, Hernandez AF, Whellan DJ, Kaul P, Schulman KA, Peterson ED, Curtis LH. Resource use in the last 6 months of life among Medicare beneficiaries with heart failure, 2000–2007. Arch Intern Med. 2011;171:196–203.
30. Li Y, Neilson MP, Whellan DJ, Schulman KA, Levy WC, Reed SD. Associations between Seattle Heart Failure Model scores and health utilities: findings from HF-ACTION. J Cardiac Fail. 2013;19:311–6.
31. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: initial catalog of health state quality factors. Med Decis Making. 1993;13:89–102.
32. Nelson AL, Cohen JT, Greenberg D, Kent DM. Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann Intern Med. 2009;151(9):662–7.
33. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.
34. Mehra MR, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, O’Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Factors associated with improvement in guideline-based use of ICDs in eligible heart failure patients. Pacing Clin Electrophysiol. 2012;35:135–45.
35. Pedretti RFE, Curnis A, Massa R, et al. Proportion of patients needing an implantable cardioverter defibrillator on the basis of current guidelines: impact on healthcare resources in Italy and the USA. Data from the ALPHA study registry. Europace. 2010;12:1105–11.
36. Al-Khatib SM, Hellkamp AS, Fonarow GC, et al. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30 % and 35 %. J Am Med Assoc. 2014;311(21):2209–15.
37. Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, Groeneveld PW, Shalaby A, Dixit S. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol. 2014;63(22):2388–94.
38. Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of 123i-mibg imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. J Am Coll Cardiol Img. 2013;6:772–84.